Neuryx

Neurological diseases share a common and devastating characteristic: by the time symptoms become visible, the damage is already advanced. Alzheimer's develops for years before memory loss becomes clinically apparent. Brain tumors have already reached significant size before producing detectable symptoms. Multiple sclerosis leaves traces in brain images long before motor or cognitive manifestations appear. The most effective intervention window — the one in which treatments have maximum impact — is often the one in which traditional diagnosis cannot yet identify the problem. Neuryx, a Swedish startup based in Stockholm, uses artificial intelligence to open that window. Neuryx's platform is an AI-based neurological diagnostics system designed for early detection of neurological pathologies through the analysis of brain imaging and other clinical data. The algorithms identify subtle patterns in images — structural, functional, connectivity-related — that escape the human eye but are predictive of the development of specific diseases. This allows conditions to be intercepted at stages when the probability of slowing progression or intervening effectively is significantly higher. The target market includes hospitals, neurology centers, specialized clinics, and research institutes managing large volumes of brain imaging. The business model is presumably SaaS or per-facility licensing, with pricing based on the volume of analyses performed or the number of clinical users. The field of AI diagnostics for neurology is one of the most active in healthtech, with growing scientific validation and a regulatory framework that is taking shape — in Europe through the Medical Device Regulation. Neuryx operates in a space where the potential clinical impact is enormous: early diagnosis of neurodegenerative diseases can make a difference not only in terms of patient quality of life, but also in costs for healthcare systems.